Some previous epidemiology studies showed that the markers for systemic inflammation, such as interleukin-6 (IL-6), [3] IL-1 receptor antagonist (IL-1Ra) [4, 5] and high sensitive C-reactive protein (hsCRP), [6] and local vascular inflammation produced in atherosclerotic lesions, such as lipoprotein-associated phospholipase A2 mass (Lp-PLA2) and activity (Lp-PLA2-A) [7] and YKL-40 [8, 9] were associated with first or subsequent stroke or functional outcome. This evidence concerns the gene PLA2G7 and Stroke.